Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Philips Medical Systems
Information provided by (Responsible Party):
Shahid Hussain, MD, University of Nebraska
ClinicalTrials.gov Identifier:
NCT01007357
First received: October 28, 2009
Last updated: June 6, 2014
Last verified: June 2014
History of Changes
  Purpose

This project will facilitate the optimization of body MR imaging at 3 Tesla.


Condition Intervention
Diffuse and Focal Abnormalities of the Liver and Pancreas
 Device: Body MR imaging

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Nebraska:

Primary Outcome Measures:
  • to optimize body MR imaging sequences [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Estimated Enrollment: 120
Study Start Date: December 2009
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Body MRI healthy volunteers
Body MRI to optimize sequences in healthy individuals and in disorder subjects
 Device: Body MR imaging
Body MR imaging will be performed to optimize sequences
Other Name: Body MR imaging performed to optimize sequences

Detailed Description:

This project is meant to improve the image quality of multiple sequences at 3.0T applied to the abdominal and pelvic regions.

  Eligibility
Ages Eligible for Study:   19 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects between ages of 19 and 65
  • Healthy volunteer subjects should not have any history of disease or symptoms - based on clinical history
  • Subjects with an underlying disorder (diffuse and focal abnormalities of the liver and pancreas)

Exclusion Criteria:

  • Inability to provide informed consent
  • A medical or contraindications that will prevent subjects from having a MRI
  • Subjects with severe renal dysfunction or patients on dialysis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01007357

Locations
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198-1045
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Sponsors and Collaborators
University of Nebraska
Philips Medical Systems
Investigators
Principal Investigator: Shahid Hussain, MD University of Nebraska
  More Information

No publications provided

Responsible Party: Shahid Hussain, MD, Principal Investigator, University of Nebraska
ClinicalTrials.gov Identifier: NCT01007357     History of Changes
Other Study ID Numbers: 290-09
Study First Received: October 28, 2009
Last Updated: June 6, 2014
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on March 01, 2015